Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients.

Kovarik JM, Neuhaus P, Cillo U, Weber M, Stitah S, Gatlik E, Meiser K, Slade A.

Transpl Int. 2011 Mar;24(3):276-83. doi: 10.1111/j.1432-2277.2010.01196.x. Epub 2010 Dec 7.

2.

Overview of sotrastaurin clinical pharmacokinetics.

Kovarik JM, Slade A.

Ther Drug Monit. 2010 Oct;32(5):540-3. doi: 10.1097/FTD.0b013e3181ee9e26. Review.

PMID:
20683390
3.

Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses.

Kovarik JM, Stitah S, Slade A, Vitaliti A, Straube F, Grenet O, Winter S, Sfikas N, Seiberling M.

J Clin Pharmacol. 2010 Nov;50(11):1260-6. doi: 10.1177/0091270009360534. Epub 2010 Apr 12.

PMID:
20386017
4.

Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients.

Kovarik JM, Steiger JU, Grinyo JM, Rostaing L, Arns W, Dantal J, Proot P, Budde K; Sotrastaurin Renal Transplant Study Group.

Transplantation. 2011 Feb 15;91(3):317-22. doi: 10.1097/TP.0b013e318203860d.

PMID:
21157403
5.

Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients.

Budde K, Sommerer C, Becker T, Asderakis A, Pietruck F, Grinyo JM, Rigotti P, Dantal J, Ng J, Barten MJ, Weber M.

Am J Transplant. 2010 Mar;10(3):571-81. doi: 10.1111/j.1600-6143.2009.02980.x. Epub 2010 Jan 29.

6.

Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.

Park JW, Siekmeier R, Merz M, Krell B, Harder S, März W, Seidel D, Schüler S, Gross W.

Int J Clin Pharmacol Ther. 2002 Oct;40(10):439-50.

PMID:
12395976
7.

Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis.

Manicassamy S.

Curr Opin Investig Drugs. 2009 Nov;10(11):1225-35. Review.

PMID:
19876790
8.

Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients.

Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES.

Am J Transplant. 2011 Jul;11(7):1444-55. doi: 10.1111/j.1600-6143.2011.03538.x. Epub 2011 May 12.

9.

Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.

Canadian Neoral Renal Transplantation Study Group.

Transplantation. 2001 Sep 27;72(6):1024-32.

PMID:
11579295
10.

Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.

Matz M, Naik M, Mashreghi MF, Glander P, Neumayer HH, Budde K.

Expert Opin Drug Metab Toxicol. 2011 Jan;7(1):103-13. doi: 10.1517/17425255.2011.540238. Epub 2010 Dec 8. Review.

PMID:
21142580
11.

Sotrastaurin and cyclosporine drug interaction study in healthy subjects.

Kovarik JM, Stitah S, Slade A, Vitaliti A, Straube F, Grenet O, Winter S, Sfikas N, Seiberling M.

Biopharm Drug Dispos. 2010 Jul;31(5-6):331-9. doi: 10.1002/bdd.715.

PMID:
20578209
12.

Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration.

Kovarik JM, Bartlett M, Rordorf C, Antunes MC, Winter S, Marbach P, van Marle S.

Int J Clin Pharmacol Ther. 2010 Feb;48(2):103-8.

PMID:
20137762
13.

Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.

Banner NR, David OJ, Leaver N, Davis J, Breen J, Johnston A, Yacoub MH.

Transpl Int. 2002 Dec;15(12):649-54. Epub 2002 Nov 22.

PMID:
12478413
14.

The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole.

Kovarik JM, Huang HL, Slade A, Sfikas N, Chandler PA.

Br J Clin Pharmacol. 2009 Sep;68(3):381-5. doi: 10.1111/j.1365-2125.2009.03457.x.

16.

[A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].

Roy A, Grant DR, Kneteman NM, Tchervenkov JI, Levy GA, Tan A, Hendricks L.

Ann Chir. 1998;52(8):716-21. French.

PMID:
9846420
17.
18.

A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.

Shenoy S, Hardinger KL, Crippin J, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.

Liver Transpl. 2008 Feb;14(2):173-80. doi: 10.1002/lt.21355.

20.

Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.

Taylor PJ, Kubler PA, Lynch SV, Allen J, Butler M, Pillans PI.

Ann Pharmacother. 2004 Feb;38(2):205-8. Epub 2003 Dec 19.

PMID:
14742751

Supplemental Content

Support Center